Royalty Pharma plc

DB:RPD Stock Report

Market Cap: €29.7b

Royalty Pharma Valuation

Is RPD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RPD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: RPD (€50.35) is trading below our estimate of future cash flow value (€179.89)

Significantly Below Future Cash Flow Value: RPD is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RPD?

Key metric: As RPD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RPD. This is calculated by dividing RPD's market cap by their current earnings.
What is RPD's PE Ratio?
PE Ratio31.7x
EarningsUS$826.29m
Market CapUS$33.81b

Price to Earnings Ratio vs Peers

How does RPD's PE Ratio compare to its peers?

The above table shows the PE ratio for RPD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.9x
MRK Merck KGaA
23.9x10.09%€60.3b
DMP Dermapharm Holding
13.9x6.91%€2.0b
SRT3 Sartorius
94.2x17.36%€13.8b
ZTS Zoetis
11.7x5.24%US$31.1b
RPD Royalty Pharma
31.7x38.57%€33.8b

Price-To-Earnings vs Peers: RPD is good value based on its Price-To-Earnings Ratio (31.7x) compared to the peer average (35.9x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does RPD's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
RPD 31.7xIndustry Avg. 21.9xNo. of Companies8PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RPD is expensive based on its Price-To-Earnings Ratio (31.7x) compared to the European Pharmaceuticals industry average (21.5x).

Price to Earnings Ratio vs Fair Ratio

What is RPD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RPD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.7x
Fair PE Ratio60.8x

Price-To-Earnings vs Fair Ratio: RPD is good value based on its Price-To-Earnings Ratio (31.7x) compared to the estimated Fair Price-To-Earnings Ratio (60.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RPD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€50.35
€52.49
+4.24%
9.43%€57.84€40.31n/a9
Jul ’27€47.73
€51.86
+8.64%
9.58%€57.76€40.26n/a8
Jun ’27€45.52
€50.30
+10.50%
9.58%€56.03€39.05n/a8
May ’27€41.64
€44.72
+7.41%
8.95%€53.73€39.23n/a9
Apr ’27€40.51
€44.61
+10.11%
7.49%€52.78€39.80n/a9
Mar ’27€37.70
€43.61
+15.68%
7.49%€51.60€38.91n/a9
Feb ’27€33.55
€40.55
+20.88%
10.25%€47.22€34.45n/a9
Jan ’27€32.83
€39.44
+20.15%
12.78%€47.69€32.36n/a9
Dec ’26€33.53
€39.68
+18.34%
13.20%€48.32€32.79n/a9
Nov ’26€31.70
€38.02
+19.95%
10.25%€46.56€32.77n/a9
Oct ’26€30.10
€38.01
+26.28%
10.97%€46.85€32.37n/a8
Sep ’26€30.43
€37.14
+22.04%
15.05%€47.20€27.63n/a8
Aug ’26€31.43
€35.87
+14.12%
14.55%€45.95€27.39n/a8
Jul ’26€30.25
€35.47
+17.25%
13.20%€43.56€27.50€47.738
Jun ’26€28.55
€37.24
+30.45%
13.20%€45.74€28.87€45.528
May ’26€28.31
€34.79
+22.87%
12.42%€41.14€28.18€41.647
Apr ’26€28.38
€37.90
+33.55%
13.80%€44.46€27.92€40.519
Mar ’26€31.94
€39.25
+22.90%
13.80%€46.05€28.91€37.709
Feb ’26€30.17
€39.01
+29.31%
17.22%€48.89€26.84€33.559
Jan ’26€24.38
€39.90
+63.68%
17.77%€49.01€26.91€32.8310
Dec ’25€24.80
€39.88
+60.80%
17.77%€48.98€26.89€33.5310
Nov ’25€25.00
€38.30
+53.20%
17.91%€47.15€25.89€31.7010
Oct ’25€25.18
€40.70
+61.62%
20.07%€54.56€25.46€30.108
Sep ’25€26.05
€40.70
+56.22%
20.07%€54.56€25.46€30.438
Aug ’25€25.92
€41.76
+61.12%
20.47%€55.22€25.77€31.438
Jul ’25€24.32
€41.66
+71.30%
20.25%€55.55€25.92€30.258
€51.09
Fair Value
1.5% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/23 06:31
End of Day Share Price 2026/07/23 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Royalty Pharma plc is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Geoffrey MeachamCitigroup Inc
Prem ChulakiCrispIdea